STIM Neuronetics

Neuronetics Announces Strategic Leadership Promotions to Support Future Growth

Neuronetics Announces Strategic Leadership Promotions to Support Future Growth

Elevated roles announced for executive team members Steve Furlong, Greg Harper and Kara Thornton

MALVERN, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced three executive leadership team promotions to support the Company’s strategic growth plans.

Effective immediately, Steve Furlong was promoted to Senior Vice President, Chief Financial Officer and Treasurer; Greg Harper to Vice President, Research & Development and Clinical; and Kara Thornton to Vice President, Human Resources. All roles report directly to Chief Executive Officer, Keith Sullivan.

“We are fortunate to have these leaders providing strategic guidance and championing our mission day in and day out,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “The executive leadership team and I share the same vision for the future of Neuronetics and I look forward to collaborating with these individuals in their elevated roles to drive the company forward. My sincerest congratulations to Steve, Greg and Kara on their achievements and well-deserved promotions.”

With more than 30 years of experience, Mr. Furlong has served as the Company’s Vice President and Chief Financial Officer since July 2019. Prior to joining Neuronetics, Mr. Furlong served as Senior Vice President, Finance at Metabolon and built his career working in the financial realm of several life sciences and medical technology companies, including Verscend Technologies, Rapid Micro Biosystems and Hologic. He received his B.A. in Political Science from The Pennsylvania State University and his Master of Finance degree from Bentley University.

Mr. Harper has more than 30 years of product development experience with global design and production teams, and has served as the Company’s Vice President, Product Development and Operations since September 2016. Prior to joining Neuronetics, he led Global Computed Tomography and Research & Development as a Vice President for Philips Healthcare and held leadership and executive positions in the Aerospace, Healthcare, and Appliance/Lighting businesses of GE. Mr. Harper holds a Bachelor of Science, Electrical Engineering degree from Valparaiso University and an MBA from the University of Wisconsin – Milwaukee.

Ms. Thornton has more than 20 years of human resources experience in the life sciences field. She has served as the Company’s Senior Director, Head of Human Resources since July 2019. Prior to joining Neuronetics, Ms. Thornton served as Head of Human Resources at Sun Pharma, where she supported the commercial and enabling businesses across five therapeutic areas. Prior to that, she held positions at several life sciences companies, including DSM, Johnson and Johnson, Bayer and Daiichi Sankyo. She holds a B.A. degree from Cabrini University in Communications and History.

These organizational updates will allow Neuronetics to continue its momentum, transforming lives and expanding awareness of its NeuroStar Advanced Therapy system for those with Major Depressive Disorder.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at .

Media Contact:

Meagan Dominick

Vault Communications

610-455-2779

 



EN
11/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatm...

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant real-world findings in the Journal of the American...

 PRESS RELEASE

Neuronetics to Report Second Quarter 2025 Financial and Operating Resu...

Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The ...

 PRESS RELEASE

Neuronetics Appoints New Chief Financial Officer

Neuronetics Appoints New Chief Financial Officer Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need...

 PRESS RELEASE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducem...

 PRESS RELEASE

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Socie...

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two signi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch